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Sequential compression biomechanical device in
patients with critical limb ischemia and
nonreconstructible peripheral vascular disease
Sherif Sultan, MD, FRCS,a,b Nader Hamada, MRCS, MCH,a Esraa Soylu, MBBCh,a
Anne Fahy, MPPM,a Niamh Hynes, MD, MRCS,a,b and Wael Tawfick, MRCSI,a Galway, Ireland
Objectives: Critical limb ischemia (CLI) patients who are unsuitable for intervention face the dire prospect of primary
amputation. Sequential compression biomechanical device (SCBD) therapy provides a limb salvage option for these
patients. This study assessed the outcome of SCBD in severe CLI patients who otherwise would face an amputation.
Primary end points were limb salvage and 30-day mortality. Secondary end points were hemodynamic outcomes (increase
in popliteal artery flow and toe pressure), ulcer healing, quality-adjusted time without symptoms of disease or toxicity of
treatment (Q-TwiST), and cost-effectiveness.
Methods: From 2004 to 2009, we assessed 4538 patients with peripheral vascular disease (PVD). Of these, 707 had CLI,
518 underwent intervention, and 189 were not suitable for any intervention. A total of 171 patients joined the SCBD
program for 3 months.
Results: All patients were Rutherford category >4. Median follow-up was 13 months. Mean toe pressure increased from
39.9 to 55.42mmHg, with amean difference in toe pressure of 15.49mmHg (P .0001).Mean popliteal flow increased
from 35.44 to 55.91 cm/s, with mean difference in popliteal flow of 20.47 cm/s (P < .0001). Mortality at 30 days was
0.6%. Median amputation-free survival was 18 months. Limb salvage at 3.5 years was 94%. Freedom from major adverse
clinical events (MACE) at 4.5 years was 62.5%. We treated 171 patients with SCBD at a cost of €681,948, with an
estimated median per-patient cost of treatment with SCBD of €3988.
Conclusion: SCBD therapy is a cost-effective and clinically efficacious solution in CLI patients with no option of
revascularization. It provides adequate limb salvage and ameliorated amputation-free survival while providing relief of
rest pain without any intervention. (J Vasc Surg 2011;54:440-7.)
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HCritical limb ischemia (CLI) is a serious condition with
dire consequences. If left untreated, patients with CLI face
the prospect of limb loss. Revascularization is not always an
option, however, due to the poor general condition of the
patient or to the absence of reconstructible vessels.1 Occlu-
sion of crural and pedal vessels in 14% to 20% of patients
with CLI makes them unsuitable for distal arterial recon-
struction.2 The Bypass Versus Angioplasty in Severe Isch-
aemia of the Leg (BASIL) trial reported that 50% of pa-
tients who had a diagnostic angiogram were unsuitable for
revascularization.3,4
Every effort must be made to identify alternative
therapies that would benefit these patients who are un-
suitable for revascularization and are deemed to be am-
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440utation bound. Sequential compression biomechanical
evice (SCBD) therapy is one such alternative. SCBD
as been shown to achieve wound healing and limb
alvage in patients with severe infrapopliteal disease and
imb-threatening ischemia who are not suitable for revas-
ularization.5-7 It increases flow to the lower limbs by
enerating improved popliteal artery blood flow, impli-
ating collateral circulation enhancement.5,7-11
Acknowledging that the evidence available to date on
CBD is anecdotal and comes mostly from feasibility stud-
es, there is still a paucity in the literature on how to care for
hese inoperable patients with limb-threatening ischemia.
e present our 4-year experience with the use of SCBD in
he management of patients with severe CLI, who are not
andidates for a revascularization procedure.
Mechanism of action. SCBD reduces venous pressure
n the dependent foot by forced emptying of capacitance
essels and expelling blood from the foot and calf to the
high.12 This increases the arteriovenous pressure gradient
nd augments arterial inflow. A suggestedmechanism is the
omentary delay in the local vasoregulation resistance of
he venoarteriolar response (VAR) and the transient sus-
ension of the arteriovenous reflex.13,14
This SCBD is delivered with the Art Assist Unit (ACI
edical, San Marcos, Calif) at a maximum inflation pres-
ure of 120 mm Hg, minimum deflation pressure of 0 mm
g, inflation rise time of 0.3 seconds, and inflation time of
seconds, followed by 16 seconds of deflation, resulting in
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Volume 54, Number 2 Sultan et al 441three compression cycles each minute. Rapid cyclic blood
flow induces high shear stress, which promotes the endo-
thelial cells to generate and release nitric oxide (NO), tissue
factor pathway inhibitor (TFPI), and endogenous tissue
plasminogen activator (tPA).15-17
METHODS
Study aim. The goal of our study was to find out the
long-term outcome of the use of SCBD as an alternative
treatment for patients with CLI who are unfit for revascu-
larization due to the nature and distribution of nonrecon-
structible peripheral vascular disease (PVD) or to severe
comorbidity scores with expected poor intervention out-
come.
Primary end points were limb salvage, sustained clinical
improvement (defined as improvement to Rutherford cat-
egory 3), and 30-day mortality. Secondary end points
were hemodynamic improvement (increase in popliteal ar-
tery flow and toe pressure), ulcer healing, quality-adjusted
time without symptoms of disease or toxicity of treatment
(Q-TwiST), and cost-effectiveness.
Patients. From June 2004 to December 2009, pa-
tients referred to our tertiary referral center with CLI were
selected to receive 90 days of a treatment protocol with an
SCBD if they had nonreconstructible arterial disease or
severe comorbidity deeming them to be too high risk for
revascularization.
Inclusion criteria. Inclusion criteria were:
1. Rutherford category 4.
2. Patient has been receiving at least 6 months of opti-
mal medical with antiplatelet, statin, and antihyper-
tensive combination, with or without anticoagulant,
if necessary.
3. Patient required more than a combination of two anal-
gesic medications, or opiates, to control rest pain.
4. American Society of Anesthesiologists (ASA) grade 4
and deemed unfit for revascularization by two consul-
tant anesthetists, or absence of any reconstructible distal
runoff vessels below the midcalf, with no outflow below
the ankle, after diligent arterial mapping (as described
below) and by consensus of at least one vascular surgeon
and one interventional radiologist.
Exclusion criteria. Twelve patients were excluded for
the following reasons:
1. Occluded popliteal artery; however, patients with a ste-
nosed popliteal artery were not excluded.
2. Extensive foot gangrene precluding attempts at limb
salvage.
3. A nonviable acutely ischemic limb.
4. Severe infection.
5. Recently confirmed deep venous thrombosis.
6. Congestive heart failure.
7. Inability to tolerate compression.
Patients were assessed on an intention-to-treat basis.
Demographic data were recorded according to the Inter-
national Classification of Diseases codes. Patients were as- sessed regarding cardiovascular risk factors and severity of
eripheral vascular disease.
Arterial mapping. Imaging was primarily by duplex
ltrasound arterial mapping (DUAM) for all CLI patients,
sing an HDI 5000 (ATL Ultrasound, Bothell, Wash) or
Phillips IU22 (Philips Medical Systems, Bothwell,
ash) with popliteal artery flow assessment and resting
oe-brachial pressure measurement.
If DUAM failed to reveal any reconstructible vessels
nd the patient was deemed unfit for surgery, then no
urther imaging was sought. If DUAM failed to show any
utflow vessels, yet the patient was deemed fit to withstand
revascularization procedure, then further imaging was
one with computed tomographic angiography (CTA) or
agnetic resonance angiography (MRA), or both.18 If
either modalities showed any reconstructible outflow, and
he patient had tissue loss and was fit for revascularization,
hen the presence or absence of any options for revascular-
zation was confirmed with on-table digital subtraction
ngiography (DSA).18
SCBD protocol. After obtaining informed consent,
atients were commenced on a treatment protocol that
asted 12 weeks5 or until they required amputation. The
herapy protocol consisted of a minimum of 6 to 8 h/d.
reatment was spread throughout the day at two inter-
als.5,7 The SCBD device was applied to the symptomatic
eg(s) while the patient was sitting upright in a chair.
atients self-administered the treatment at home by wear-
ng the inflatable cuffs on the foot and calf. At the end of the
2 weeks, if the patient’s rest pain was improving, or the
lcer was reducing in size, yet their symptoms had not
ompletely resolved, then a second 12-week protocol was
ommenced. All patients were treated with aspirin, clopi-
ogrel, amlodipine, and a statin.
Data collection. Data were prospectively collected
nto a prospectively customized vascular database based on
ascuBase 5.9 (Consensus Medical Systems Inc, Rich-
ond, BC, Canada). The generic VascuBase software was
ustomized to allow it to cover any data not routinely
ollected by VascuBase.
Follow-up. Follow-up was at 30 and 90 days and at
egular 6-month intervals. Patients were assessed clinically
t each visit for resolution of rest pain, ulcer healing, and
mprovement of gangrene. Doppler pressure measure-
ents and popliteal duplex scanning were performed.
Cost analysis. Cost data were obtained from the hos-
ital patient accounting database. Total costs included the
osts of the SCBD, hospital bed occupancy (during the
nitial work-up phase or any subsequent PVD-related hos-
italizations required by the patient), physician fees, oper-
ting room services, imaging and investigations, medica-
ion, and other services related to the treatment.
Statistical methods. Descriptive statistics were used
or patient demographic characteristics. A paired t test was
sed to compare the arterial flows before, during, and after
he application of SCBD. Data were expressed as a mean
tandard deviation and 95% confidence intervals (CIs).
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August 2011442 Sultan et alFor those patients who died before the study comple-
tion at 18 months, the data last accumulated were consid-
ered for an intention-to-treat analysis. Data are expressed as
median and interquartile range (IQR). The level for statis-
tical significance was set at P  .05.
RESULTS
Patients. From 2004 to 2009, we reviewed 4538
patients with PVD. Of these, 707 presented with CLI, 518
had one or more interventions for PVD, and 189 were not
candidates for surgery. Only 171 patients (63% men) met
the inclusion and exclusion criteria and agreed to join the
SCBD program for 3 months at 3 hours bi-daily. Patients
were a median age of 75 years. More than half were
smokers, hypertensive, with dyslipidemia and hyperhomo-
cysteinanemia (Table I). All patients were Rutherford cat-
egory 4, 5, or 6, and 47% were classed as ASA grade 4 by
two consultant anesthetists. The mean absolute toe pres-
sure was 39.9 mm Hg, and the mean popliteal artery flow
was 35.44 cm/s (Table II).
No tibial vessel runoff was documented in 59% patients.
All patients had multilevel vessel involvement, 87% had
superficial femoral artery involvement, 20% had a diseased
popliteal artery, 71% had tibioperoneal trunk involvement,
Table I. Demographics and risk factors in 171 patients
with sequential compression biomechanical device
therapy
Variable No. (%) or Median (IQR)
Age, years 75 (68-81)
Males 107 (63)
Diabetes mellitus 67 (40)
Hypertension 87 (51)
Ischemic heart disease 82 (48)
Dyslipidemia 87 (51)
Renal impairmenta 32 (19)
Smokingb 114 (67)
Hyperhomocysteinemia 90 (53)
IQR, Interquartile range.
aDefined as creatinine 150 mg/dL.
bDefined as a current smoker or a smoker who stopped during the past 5
years.
Table II. Clinical presentation of 171 patients with
sequential compression biomechanical device therapy
Variable No. (%) or Median
ASA 4 80 (47)
Ulcer duration, months 14 (6-23)
Ulcer surface area, cm2 28 (19-41)
Rutherford category 5 and 6 126 (74)
Duration of symptoms, months 24 (14-34)
Ankle-brachial index 0.36 (0.11-0.48)
Toe pressures, mm Hg 39.9 (12.4-51.8)
Popliteal flow, cm/s 35.44 (16.1-58.2)
ASA, American Society of Anesthesiologists.and 83% had at least one diseased tibial vessel (Table III). pen patients (6%) were not suitable for revascularization
ecause they had no reconstructible vessels and a high ASA
rade, 70 patients (41%) were deemed not suitable for
evascularization due to high ASA grade, and 91 patients
53%) had no reconstructible vessels (Table IV). All pa-
ients received optimum medical therapy.
All patients completed at least one 12-week cycle of
herapy. Of these, 31 (18%) needed a second 12-week cycle
o help completely resolve their rest pain. The median
ollow-up after the end of the therapy cycle was 13 months,
ith an average of 18.3 months (range, 1-62 months).
End points. Sustained hemodynamic improvement
as noted with an increase in mean toe pressure from 39.9
o 55.42 mmHg after treatment, with a mean difference in
oe pressure of 15.49  30.92 mm Hg (95% CI, 8.06-
2.92 mm Hg; P  .0001). This increase was sustained at
2 months of follow-up (Table V).
Mean popliteal flow increased from 35.44 to 55.91
m/s after treatment, with a mean difference in popliteal
ow of 20.47  46.22 cm/s (95% CI, 14.02-26.91 cm/s;
 .0001). This improvement was maintained at 12
onths of follow-up (Table V).
Rest pain resolved in all patients by the end of their one-
r two-cycle treatment period. Gangrene remained dry and
onprogressive. Ulceration healed in all but five patients,
ho required a major amputation. No device-related com-
able III. Vessels involved and distal vessel runoff in
atients who received sequential compression
iomechanical device therapy
ariable No. (%)
otal patients 171 (100)
ortoiliac segment 19 (11)
ommon femoral artery 30 (18)
uperficial femoral artery 149 (87)
opliteal artery 35 (20)
ibioperoneal trunk 122 (71)
nterior tibial artery 130 (76)
osterior tibial artery 111 (65)
eroneal artery 126 (74)
cclusive lesions 142 (83)
o distal runoff 101 (59)
essel runoff
1 vessel 27 (16)
2 vessels 14 (8)
3 vessels 29 (17)
able IV. Reason patients were deemed not suitable for
evascularization
ariable No. (%)
otal patients 171 (100)
nfit for surgery, nonreconstructible vessels 10 (6)
nfit for procedure only (ASA 4) 70 (41)
onreconstructible disease only 91 (53)
SA, American Society of Anesthesiologists.lications were reported.
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Volume 54, Number 2 Sultan et al 443Clinical improvement where the patient reverted to
Rutherford category 3 was achieved in 161 patients
(594%). Sustained improvement at 3 years of follow-up was
30% (Fig 1). Median amputation-free survival was 18
months, with a limb salvage rate of 94% at 3.5 years (Fig 2).
Freedom from MACE was 63% at 4.5 years (Fig 3).
The 30-day mortality was 0.6%, and all-cause survival
was 31% in SCBD patients at 4 years (Fig 4). All-cause
survival was 63% (50 of 80) at 4 years in patients with a high
ASA compared with 13% (n  12 of 91) in patients with
nonreconstructible disease only (P  .0001). Cardiac or
respiratory comorbidities were the cause of death in 54
patients, five of whom required an amputation before
death. Vacuum-assisted closure was used in conjunction
with SCBD in 75 legs (44%).
Cox proportional hazard modeling showed that smok-
ing, diabetes mellitus, chronic renal failure, hypertension,
and hypercholesterolemia did not have a significant effect
on limb salvage or toe pressure improvement.
The mean cost of managing a patient with SCBD,
including device rental, hospital visits, physician fees, imag-
ing and investigations, medication, and follow-up was
Table V. Hemodynamic improvement at 12-months of fo
Hemodynamic improvement
Pre-SCBD Post-
Mean M
Ankle-brachial index 0.36 0
Toe pressure, mm Hg 39.9 55
Popliteal flow, cm/s 35.44 55
SCBD, Sequential compression biomechanical device.
aThere was a significant improvement in the ankle-brachial index, toe pressu
bPaired t test.
Fig 1. The Kaplan-Meier curve shows the time with sustained
clinical improvement (patients alive and in Rutherford category 3)
was 30% at 3 years in patients who received therapy with the
sequential compression biomechanical device (SCBD). The stan-
dard error was 10.2% at 36 months.€3988 per patient (Table V). Q-TWiST was 38.13 for a wotal of 606 months of ArtAssist usage (Table VI). Factor-
ng in the cost of those patients who underwent major
mputations, the cost per quality-adjusted life year for
CBD was €2,953 (Table VII).
ISCUSSION
CLI affects 765/1 million individuals each year; of
hese, 30% will undergo an amputation within the first
ear after diagnosis. The 5-year mortality rate for CLI
atients is 70%, and most of these deaths are cardiovas-
ularly related.19-22 It is challenging to portray the natural
istory of CLI; therefore, management strategies must be
astered, and the cardiovascular burden should be ac-
nowledged and managed aggressively.
Longitudinal comparison studies for the incidence of
mputations signal an increase, ascribed to the cardiovas-
ular atherosclerosis burden, pandemic of diabetesmellitus,
nd the aging population.23-25 This is predicted to lead to
he number of major amputations being tripled within 2
ecades.
Eskelinen et al26 conveyed that when bypass surgery
as meticulously practiced for CLI, 1976 major amputa-
ions/1 million were done in contrast to 3177/1 million
-upa
Change 95% CI Pb
0.14 0.03-0.26 .018
15.49 8.06-22.92 .0001
20.47 14.02-26.91 .0001
nd popliteal artery flow velocity.
ig 2. The Kaplan-Meier curve shows an amputation-free sur-
ival limb salvage rate of 94% at 3.5 years in patients who received
herapy with the sequential compression biomechanical device
SCBD). Standard error was 6% at 40 months.llow
SCBD
ean
.50
.42
.91hen bypass surgery was performed as a last resort for limb
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August 2011444 Sultan et alsalvage. There is still a paucity of data in the literature
regarding the traditional logic of action when revascu-
larization has been exhausted or is not practical. This
provoked us to appraise the clinical efficacy of SCBD in
Fig 3. The Kaplan-Meier curve shows freedom from major ad-
verse clinical events was 63% at 4.5 years in patients who received
therapy with the sequential compression biomechanical device
(SCBD). The standard error was 10.7% at 55 months.
Fig 4. The Kaplan-Meier curve shows all-cause survival at 4 years
was 31% in patients who received therapy with the sequential
compression biomechanical device (SCBD). The standard error
was 6% at 4 years.
Table VI. Quality time spent without symptoms of
disease and toxicity of treatment (Q-TWiST)
Variable Outcome
Toxicity (time with toxicity of disease), months 4.63
TWiST (time w/o symptoms of disease or toxicity
of treatment), months 33.03
Progress (time with progression of disease), months 5.56
Q-TWiST 38.13amputation-bound CLI patients. sPatient-oriented outcome end points and health-
elated quality of life and functional status, are entering a
ew phase by replacing the traditional vascular surgeon–
riented or lesion-oriented outcomes. This new paradigm
hift is crucial for the most favorable applicable manage-
ent opportunities for CLI patients. As gauged by “ideal”
utcomes, optimal results in CLI revascularization are sel-
om achieved. This will become increasingly important
rom a public health standpoint as the population of CLI
atients and the number of treatment alternatives contin-
es to escalate.
Interventions in 14% of CLI patients are typically un-
omplicated, with relief of symptoms, complete wound
ealing, no prerequisite for repeat operation, and mainte-
ance of functional status. For the rest of the 86% of CLI
atients, however, repeated hospitalizations will be re-
uired for numerous interventions, with declining func-
ional status.19
Although limb salvage will persist to be the paramount
mbition for most patients referred for vascular surgery
nterventions, some patients with CLI are undoubtedly
etter served with amputation. Regrettably, it is not con-
tantly apparent beforehand which patients will gain from
rimary amputation vs limb salvage endeavor.
Our study showed an increase in the toe-brachial index.
his acknowledges the work of Husmann et al27 on skin
lood-flow augmentation with SCBD due to transient sus-
ension of the precapillary sphincter and enhancing skin mi-
rocirculation in CLI patients as the VAR is abolished. How-
ver, our results contradict the findings of Wahlberg et al28
nd Cisek et al29 that diabetic patients will not benefit from
CBD, on the assumption that VAR is impaired because of
eripheral sympathetic postural auto-vasoregulation. Forty
ercent of our study was in diabetic patents, and the Cox
roportional hazard ratio showed that diabetes mellitus,
hronic renal failure, and hypercholesterolemia had no signif-
cant effect on limb salvage or toe pressure measurement. We
o acknowledge, however, that only 67 patients had diabetes,
o the small number of patients needs to be taken into con-
able VII. Cost of sequential compression
iomechanical device (SCBD) therapy
ost Cost, €
ost of SCBD rental
Per patient, 12-week protocol 1600
Total, including second 12-week protocol 323,200
otal cost of medical therapy (not amputations)a 358,748
ost of SCBD rental
Total cost and hospital visits 681,948
Cost plus hospital visits per patient 3988
ost of amputation per patientb 29,815
otal amputation cost (11 amputees) 327,965
verall total cost 1,009,913
ost per quality-adjusted life-year 2953
Includes hospital visits, physician fees, imaging and investigations, medica-
ion, and follow-up.
Including hospitalization, surgery, and rehabilitation.ideration when interpreting this.
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Volume 54, Number 2 Sultan et al 445Delis et al30,31 and Husmann et al32 had established
that arterial vascular intervention is associated with a rever-
sal of peripheral vasodilatation with correction of impaired
VAR because of the chronic ischemia and decrease in both
arterial calf inflow and skin flux on dependency, suggesting
readjustment of peripheral resistance.
Applying the same concept to our SCBD patients dem-
onstrated that rest pain reduction and ulcer healing were
witnessed within the first week, because of a transient
attenuation of the VAR during SCBD application, and it
might be one of the mechanisms that provide blood flow to
the lower limb. These findings contradict the traditional
assumption that arterioles in CLI patients “maximally di-
lated,” due to peripheral sympathetic autoregulation. This
autoregulation is considered to be abolished in CLI, a
phenomenon known as vasomotor paralysis, and they are
relatively insensitive to vasodilator stimuli.12,13 Yet epidural
anesthesia33 and the administration of prostaglandins,34,35
both causing attenuation of peripheral flow resistance with
vasodilatation, have been reported to offer an appreciable
clinical improvement, thus contradicting the contention of
peripheral vasoparalysis in CLI.
Delis et al30 noted that SCBD increases blood flow,
relieves rest pain, and limits tissue damage in CLI patients
by generating a threefold to fourfold augmentation in
popliteal artery blood flow. This mimics our findings in
patients with a normal or stenosed popliteal artery.
We like others documented hyperemia after SCBD,
and the pronouncement by Abu-Own et al36 that SCBD
lowers peripheral vascular resistance with the liberation of
endothelial-derived relaxing factors is well established.
Nevertheless, their effects are not virtuously mechanical
and the liberations of biochemical mediators are impor-
tant.24
Our protocol for SCBD of 90 days with 3 hours in the
morning and in the evening materialized from the work of
van Bemmelen et al,37 as it was apparent that the greatest
improvement occurred in the first 3 months of treatment.
Improvement in blood flow was sustained after SCBD
usage.8
We concur with the annotations of van Bemmelen et al5
and Montori et al7 where the relationship between patient
compliance and clinical outcome was pragmatic. Those in
whom limb salvage was attainedmade use of SCBD accord-
ing to the protocol, compared with 11 patients in whom
SCBD failed.
Analysis of our hospital inpatient accounting database
shows a cost of €17,300 for inpatient hospitalization for
CLI for angioplasty and successful distal bypass. Con-
versely, SCBDoffers a cost-effective opportunity in patients
who are unsuitable for revascularization. The cost of using
an SCBDmachine is €3,988 per patient. SCBD can be used
to treat four CLI patients for the same cost of operating on
one CLI patient. Our figures are comparable to those of
Delis et al.8 Our cost analysis reveals that the price of
treating eight patients with SCBD is approximately the
same as the cost of one primary amputation. In our institu-
tion, the hospitalization cost alone for primary amputation,ithout home modification and long-term rehabilitation
osts, was €29,815.
The cost per quality-adjusted life year for SCBD was
2,953. Q-TWiST was 38.13 for a total of 606 months of
CBD treatment. Wemanaged 171 end-stage CLI patients
ith impending limb loss, at a cost of €681,948, with a
easonable limb salvage rate.
ONCLUSIONS
SCBD is a valuable tool in the armamentarium of
ealing with patients who have CLI with nonrecon-
tructible PVD. It provides ameliorated amputation-free
urvival, rapid relief of rest pain, and enhanced rates of ulcer
ealing. This is achieved with reduced hospital length of
tay and without any intervention in patients with a limited
ife expectancy and impending limb loss.
This study provides larger-scale evidence that SCBD
herapy is a cost-effective and clinically efficacious solution
or treatment of high-risk patients with nonreconstructible
ower limb arterial disease with enhanced QALY and better
TWiST.
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DrAlanDardik (NewHaven, Conn). Dr Sultan, did you have
any other options besides the ArtAssist device for this patient,
something like stem cell therapy or growth factor therapy?
Dr Sherif Sultan. Regarding stem cell therapy, we haven’t
applied it in our practice yet due to prohibitory national regula-
tions. However, it might soon be an option. But the results from
clinical trials that have been conducted have been far from con-
vincing. Stem cell therapy is still in its infancy and it has a long way
to go before it forms a cornerstone of our treatment. That said,
some of the cultured stem cells are showing some promise but are
still far away from applying to clinical practice.
Dr Hasan Dosluoglu (Buffalo, NY). Very good results, but I
am very confusedwith the results because it looks not only better than
primary amputation but better than those who undergo revascular-
ization. As a matter of fact, the reported survival is better than
claudicants in our series. It seems tome that this is a very unique groupetter, because, as I said, it is not your typical critical limb ischemia
CLI) group, just by looking at the 68% 5-year survival rate.
Dr Sultan. First of all, these patients are very high risk. From
hen you first see them in your clinic, these are the guys that have
he sign on them saying “do not touch!” And basically if you don’t
ouch them, they’ll survive until they are going to die from their
ardiovascular comorbid-laden problems. One of the reasons that
e have a good outcome is because these patients die from
omething else rather than dying from their legs. And this is borne
ut in the Kaplan-Meier curves. The minute you touch these
atients they die, and this is evident from the 12 patients that we
id intervene on, all of them are dead. That is the problem. They
re very fragile and there is no way back for them.
Dr Hisham Bassiouny (Chicago, Ill). Can you elaborate on
our strategy to maintain patient compliance for applying the
evice three times daily for 1 hour during the duration of the
tudy?
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the morning and 3 hours in the evening. And some patients use it
more than that and are very compliant. One of the major things
that we discovered is that when you offer it to the patient, you have
to give them at least 2 to 3 days in the hospital to give them the
opportunity to build a “friendly relationship” with the machine. If
you give them the machine as an outpatient, they’re usually afraid
of using it. But the minute they get their heads around it, they fare
out brilliantly. In fact, some of my patients have already bought
this machine and they don’t want to give it back to the company.
Dr Peter Gloviczki (Rochester, Minn). If I understood your
data correctly, the results are as good as with open revasculariza-
tion. So do you still perform open revascularization in those who
are suitable for distal bypass?
Dr Sultan. We are very aggressive with our CLI program and
are fully committed to thoracic endovascular aneurysm repair
(TEVAR) revascularization, whether angioplasty alone or laser
angioplasty. Revascularization remains our prime aim for these
patients. We only offer the ArtAssist machine, because of our
problem with funding, to patients that are not suitable for TEVAR
if they have absolutely no runoff vessel or they are very high risk.
Dr Dardik. So if you can tell us, these patients all had only
distal disease or did they have, for example, superficial femoral
artery occlusion and then you were unable to revascularize them?
Dr Sultan. These patients, when you do your duplex, there is
no runoff vessel traveling from the distal calf to the ankle and the
toes. That’s the first thing.
n
9The other thing that we have found is that a patent popliteal
rtery is crucial for the success of the use of this. The inflow-
utflow is a problem, but definitely the presence of a patent
opliteal is the only way that you can ensure the successful use of
his machine.
Dr Dardik. Any contraindications to use of this machine?
Dr Sultan. Severe congestive cardiac failure and deep vein
hrombosis (DVT) are two of the major contraindications and that
s why we usually keep some of our patients in the hospital initially
ust to offload a few liters of fluid out of their body before we put
he machine on, otherwise you could drive into acute pulmonary
dema. DVT is definitely a contraindication.
Dr Samir Issa (Riyadh, Saudi Arabia). We passed on very
ast the changes in the toe brachial index. Could you please
laborate on the objective change in this parameter? Did you
otice any improvement in the toe brachial index after using this
evice?
Dr Sultan. There is a theory that there is a vascular plegia
roblem in the precapillary area in these patients, especially in
iabetics. Evidence has shown that when an epidural or prostaglan-
in is given to these patients that there is peripheral vasodilatation
nd the patients benefit tremendously. We measure the digital
ressure and we measure laser Doppler values in these patients.
lthough we don’t have a full set of data from the laser Doppler,
e do have a complete set of ankle brachial indices and the digital
ressures. The ankle brachial indices have improved significantly in
ondiabetic patients. While digital pressures have improved after
0 days in all patients who completed the program.
